Analyst Price Target is $43.40
▼ -26.83% Downside Potential
This price target is based on 6 analysts offering 12 month price targets for Progyny in the last 3 months. The average price target is $43.40, with a high forecast of $64.00 and a low forecast of $32.00. The average price target represents a -26.83% upside from the last price of $59.31.
Current Consensus is
The current consensus among 6 polled investment analysts is to buy stock in Progyny.
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.